Log in

Relevant bibliographies by topics / Role of HR directors / Journal articles

To see the other types of publications on this topic, follow the link: Role of HR directors.

Journal articles on the topic 'Role of HR directors'

Author: Grafiati

Published: 4 June 2021

Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Role of HR directors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Brooks, Wendy. "Elevating the role of HR directors." Human Resource Management International Digest 15, no. 5 (2007): 42–46. http://dx.doi.org/10.1108/09670730710762898.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Laane, Edward, Purushothama Nanjappa, Subodh Kumar, et al. "XRCC5 Plays an Important Role in Homologous Recombination, Genome Stability and Survival of Myeloma Cells." Blood 126, no. 23 (2015): 1218. http://dx.doi.org/10.1182/blood.v126.23.1218.1218.

Full text

Abstract:

Abstract Understanding mechanisms underlying genomic instability is critical in delineating pathogenesis and development of new treatments for prevention and treatment of cancer. We have previously shown that dysregulated homologous recombination (HR) significantly contributes to genomic instability and progression in multiple myeloma (MM). To identify the regulators of HR and genome stability in MM, we conducted a functional shRNA screen and identified XRCC5 (Ku80) as a novel regulator of HR in MM cells. XRCC5 has been known to work as part of DNA ligase IV-XRCC4 complex in the repair of DNA

APA, Harvard, Vancouver, ISO, and other styles

3

Albrecht, Chad, Tim Gardner, Scott Allred, Brad Winn, and Adam Condie. "To sit at the table, you have to know the language: important financial metrics for HR directors." Strategic HR Review 15, no. 3 (2016): 123–28. http://dx.doi.org/10.1108/shr-02-2016-0021.

Full text

Abstract:

Purpose The main thrust behind strategic human resources (HR) includes strengthening the impact of HR on the organization. In other words, strategic HR attempts to place the HR department on equal footing with other functional areas of business. HR professionals who understand both operational indicators and their decisions on various financial metrics have greater focus and clarity when making decisions. HR professionals with such knowledge are also more likely to be viewed favorably by their counterparts in other departments and have a greater voice in the executive suite and boardroom. Desi

APA, Harvard, Vancouver, ISO, and other styles

4

Hota, Deepak Kumar. "View from Helm: Corporate Governance Through HR Prism." NHRD Network Journal 12, no. 4 (2019): 328–34. http://dx.doi.org/10.1177/2631454119873157.

Full text

Abstract:

The rigorous corporate governance frameworks in Company Law and Securities and Exchange Board of India regulations, have not prevented incidents of fraud in listed companies in India. The top management should therefore play a critical role, by fostering desirable organisational culture, clarifying clear boundaries of organisational behaviour and also enunciating value statements and requisite policies in the company. Bharat Earth Movers Limited (BEML) (see https://www.bemlindia.in/ ) which is in a tough and competitive business environment, has codified its values statement ‘BEML FIRST’ (Focu

APA, Harvard, Vancouver, ISO, and other styles

5

Cavo, Michele, Hartmut Goldschmidt, Laura Rosinol, et al. "Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies." Blood 132, Supplement 1 (2018): 124. http://dx.doi.org/10.1182/blood-2018-99-112899.

Full text

Abstract:

Abstract Introduction: Conflicting results from two recently reported randomized studies comparing double vs single autotransplantation (ASCT) for newly diagnosed multiple myeloma (MM) patients (pts) [(Cavo M et al, Blood 2017;130(1); Stadtmauer EA et al, Blood 2016;128(22)] are likely to reflect differences in the design of the trials. To address this controversial issue, we performed a long-term follow-up analysis of pt-level data from three phase 3 trials of bortezomib-thalidomide-dexamethasone (VTD) (Cavo M et al, Lancet 376; 2075-85, 2010; Rosinol L et al, Blood 120; 1589-96, 2012) or bor

APA, Harvard, Vancouver, ISO, and other styles

6

Gunesh, Priya, and Vishwas Maheshwari. "Role of organizational career websites for employer brand development." International Journal of Organizational Analysis 27, no. 1 (2019): 149–68. http://dx.doi.org/10.1108/ijoa-01-2018-1327.

Full text

Abstract:

PurposeThe paper aims to demonstrate the utilization of banks’ career website for publicizing the employer branding strategy to enable effective strategic talent relationship management through talent attraction, engagement and retention.Design/methodology/approachA qualitative approach using purposive sample comprising HR professionals involving HR directors, reward managers and talent relationship managers, participated in semi-structured interviews.FindingsThis paper provides empirical insights on the use of career websites to disseminate the employer brand. The findings reveal the presence

APA, Harvard, Vancouver, ISO, and other styles

7

Bessant, Ceridwyn, and Sharon Mavin. "Neglected on the front line." Journal of Management Development 35, no. 7 (2016): 916–29. http://dx.doi.org/10.1108/jmd-09-2014-0105.

Full text

Abstract:

Purpose – The purpose of this paper is to investigate the first-line manager-academic (FLMA) role against a guiding hypothesis that “The first-line manager-academic role is not clearly defined or understood; there is great variety of practice and of recognition of the role across the business school sector”. Design/methodology/approach – A descriptive, deductive approach through three linked (internet) surveys of deans of UK business schools, FLMAs in UK business schools and UK university human resource directors. Findings – The FLMA role in UK business schools is important to organizational e

APA, Harvard, Vancouver, ISO, and other styles

8

D'Agostino, Mattia, Anders Waage, Juan-José Lahuerta, et al. "Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform." Blood 134, Supplement_1 (2019): 1773. http://dx.doi.org/10.1182/blood-2019-124321.

Full text

Abstract:

Background. The outcome of multiple myeloma (MM) patients is heterogeneous. In 2015, analyzing 4445 newly diagnosed MM (NDMM) patients enrolled into 11 clinical trials after a median follow-up of 46 months, a risk stratification algorithm named Revised-ISS (R-ISS) was developed combining International Staging System (ISS), chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization and serum lactate dehydrogenase (LDH) (Palumbo et al., JCO 2015). Here we report a mature follow-up of 5584 patients enrolled in 14 clinical trials, providing an updated report on the R-I

APA, Harvard, Vancouver, ISO, and other styles

9

Nanjappa, Purushothama, Subodh Kumar, Srikanth Talluri, et al. "Critical Role of Split Hand/Foot Malformation Type 1 (SHFM1) in Homologous Recombination and Cell Survival in Multiple Myeloma (MM)." Blood 126, no. 23 (2015): 3625. http://dx.doi.org/10.1182/blood.v126.23.3625.3625.

Full text

Abstract:

Abstract Genomic instability is associated with development and progression of cancer. Our previous studies have demonstrated that myeloma cells display a marked genomic instability and the number of mutations correlates with clinical outcome. Based on published observation that dysregulated homologous recombination (HR) contributes to genomic instability in multiple myeloma (MM) we have investigated mechanisms underlying dysregulated HR. We conducted a functional high-throughput shRNA screen using HR assay and identified Split hand/foot malformation type 1 (SHFM1) as a novel regulator of HR i

APA, Harvard, Vancouver, ISO, and other styles

10

De Beer, Frank, and Daniel Hercules Du Toit. "Human resources managers as custodians of the King III code." South African Journal of Economic and Management Sciences 18, no. 2 (2015): 206–17. http://dx.doi.org/10.4102/sajems.v18i2.769.

Full text

Abstract:

The objective of this research was to perform an exploratory study on the knowledge and understanding of the King III code among Human Resources (HR) managers in South African companies. The King III code is a comprehensive international corporate governance regime which addresses the financial, social, ethical and environmental practices of organisations. HR management plays a role in managing corporate governance by using the King III code as a guideline. The main research questions were: Does HR management know, understand, apply, and have the ability to use the King III code in terms of et

APA, Harvard, Vancouver, ISO, and other styles

11

Cavo, Michele, Hans Salwender, Laura Rosiñol, et al. "Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies." Blood 122, no. 21 (2013): 767. http://dx.doi.org/10.1182/blood.v122.21.767.767.

Full text

Abstract:

Abstract In the novel agent era, the role of double autologous transplantation (ASCT) as up-front therapy for MM still remains undefined. Recently, several European cooperative groups prospectively compared bortezomib-based vs non-bortezomib-based induction regimens before ASCT for newly diagnosed myeloma (MM). By study design, patients enrolled into these trials were prospectively assigned to receive either a single or double ASCT. A multivariate regression analysis revealed that the leading factors independently associated with shorter PFS and OS were ISS 3, presence of high-risk cytogenetic

APA, Harvard, Vancouver, ISO, and other styles

12

Mayo, Andrew. "HR at the top table." Strategic HR Review 19, no. 6 (2020): 259–65. http://dx.doi.org/10.1108/shr-08-2020-0074.

Full text

Abstract:

Purpose The purpose of this paper is to examine the aspiration of Human Resources (HR) professionals to “be at the top table”; what that means; and how such professionals can become highly valued members of business teams. Design/methodology/approach The paper discusses what is meant by “top table” and the ambitions of HR professionals to be there. It looks at the prevalence of HR in top teams; how professionals are prepared for senior roles; and it provides a model for effective top team membership. Findings The paper discusses the statistics of HR directors in top teams and concludes it shou

APA, Harvard, Vancouver, ISO, and other styles

13

Park, Ji Sung, and Seongmin Ryu. "The Search for Indicators of the Differentiation of HR Departments’ Strategic Role and the Future Research Directions for HR Roles." Korean Academy of Management 25, no. 4 (2017): 15–44. http://dx.doi.org/10.26856/kjom.2017.25.4.15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Desai, Pinkal, Samuel Handelman, Alan Wu, et al. "Antecedent Clonal Hematopoesis and Risk of and Mortality after Solid and Hematological Malignancies: Analyses from the Women's Health Initiative Study." Blood 134, Supplement_1 (2019): 1199. http://dx.doi.org/10.1182/blood-2019-131862.

Full text

Abstract:

Background: Whole genome analyses of peripheral blood has demonstrated that acquired somatic mutations in peripheral blood also known as clonal hematopoiesis of indeterminate potential (CHIP) is present in up to 10% of individuals older than 60 years and associated with increased risk of cardiovascular mortality and hematologic malignancies (Jaiswal et al, Genovese et al, NEJM 2014). We have demonstrated that CHIP is associated specifically with increased risk of leukemia (Desai et al, Nat. Medicine 2018). CHIP has also been detected in 25% of individuals with concomitant advanced solid malign

APA, Harvard, Vancouver, ISO, and other styles

15

Zamagni, Elena, Cristina Nanni, Luca Dozza, et al. "Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials." Blood 132, Supplement 1 (2018): 257. http://dx.doi.org/10.1182/blood-2018-99-111321.

Full text

Abstract:

Abstract F-18-fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) is actually considered as the standard technique to assess and monitor the metabolic response to therapy and to define minimal residual disease (MRD) status outside the bone marrow (BM) in multiple myeloma (MM) patients. In this regard, standardization of image criteria and definition of cut-offs for positivity/negativity is of highly importance. Aim of the present study was to prospectively evaluate FDG-PET/CT at diagnosis and prior to maintenance therapy in a joined analysis of a su

APA, Harvard, Vancouver, ISO, and other styles

16

Alhumaid, Muhned, Georgina S. Daher-Reyes, Aaron D. Schimmer, et al. "Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation." Blood 136, Supplement 1 (2020): 8–9. http://dx.doi.org/10.1182/blood-2020-138862.

Full text

Abstract:

BACKGROUND: Multiparameter flow cytometry (MFC) has increasingly been used for measurable residual disease (MRD) assessment in patients with acute myeloid leukemia (AML), while next-generation sequencing (NGS)-based MRD monitoring tool is in clinical development for its application. Clonal hematopoiesis (CH), in which leukemia-associated somatic mutations gene are present in individuals with no apparent hematologic disease, adds a challenge in the detection of MRD. In patients with AML, CH could be potentially pre-leukemic, while persistent mutations in DNMT3A, TET2 orASXL1 (DTA) in remission

APA, Harvard, Vancouver, ISO, and other styles

17

Schjesvold, Fredrik H., Paul G. Richardson, Michel Attal, et al. "Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis." Blood 134, Supplement_1 (2019): 1893. http://dx.doi.org/10.1182/blood-2019-128010.

Full text

Abstract:

INTRODUCTION: Multiple myeloma (MM) is most frequently diagnosed among people aged 65-74, and approximately one-third of patients (pts) are aged ≥75 years. Advanced age has a negative effect on the prognosis of pts with MM. The randomized, open-label, active-controlled, multicenter phase 3 ICARIA-MM study (NCT02990338) compared treatment with the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with pomalidomide and dexamethasone (Pd) with Pd. Pts had relapsed/refractory MM (RRMM) after ≥2 prior lines of therapy, including lenalidomide and a proteasome inhibitor. This subgroup ana

APA, Harvard, Vancouver, ISO, and other styles

18

Pal, Jagannath, Jeffrey Sawyer, Samir B. Amin, et al. "Elevated Homologous Recombination Induces Karyotypic Changes and Predicts Poor Clinical Outcome In Multiple Myeloma." Blood 116, no. 21 (2010): 1924. http://dx.doi.org/10.1182/blood.v116.21.1924.1924.

Full text

Abstract:

Abstract Abstract 1924 Homologous recombination (HR), by inducing DNA rearrangements, plays an important role in cancer cell proliferation and progression via induction of oncogene activation, and/or anti-oncogene inactivation (or loss of heterozygosity at tumor suppressor loci), as well as telomere-expansion. We have observed that recombinase (RAD51) expression and homologous recombination (HR) activity are constitutively elevated in multiple myeloma (MM) as well as other cancers, and the suppression of recombinase (hsRAD51) reduces HR and significantly inhibits genomic instability and develo

APA, Harvard, Vancouver, ISO, and other styles

19

Tacchetti, Paola, Serena Rocchi, Luca Dozza, et al. "Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma." Blood 134, Supplement_1 (2019): 1796. http://dx.doi.org/10.1182/blood-2019-128715.

Full text

Abstract:

Introduction: The role of serum free light chain (sFLC) assay for monitoring immunoglobulin (Ig) secretory multiple myeloma (Ig-MM) remains an area of debate. IMWG guidelines (Durie et al. Leukemia 2006) recommend the use of electrophoresis (EP) and immunofixation (IF) for definitions of response and progressive disease (PD), while the measurement of sFLC is required only to fulfill criteria for stringent complete response. Aims: We aimed at evaluating the prognostic impact of sFLC levels during monitoring of Ig-MM. Methods: We analyzed all consecutive Ig-MM patients (pts) who received at our

APA, Harvard, Vancouver, ISO, and other styles

20

Held, Gerhard, Samira Zeynalova, Niels Murawski, et al. "The Impact of Rituximab and Radiotherapy On Treatment Outcome of Patients with DLBCL and Skeletal Involvement." Blood 120, no. 21 (2012): 690. http://dx.doi.org/10.1182/blood.v120.21.690.690.

Full text

Abstract:

Abstract Abstract 690 Background: There is limited information on the role of skeletal involvement in DLBCL patients treated with rituximab. Methods: In a retrospective subgroup analysis patients with aggressive B-cell lymphomas with and without skeletal involvement were compared with respect to clinical presentation, event-free and overall survival. Results: Of 3840 patients 292 (7.6%) had skeletal involvement. In a multivariable analysis of patients treated within the randomized MInT and RICOVER-60 trials, the two largest randomized trials addressing the role of rituximab in DLBCL to date, s

APA, Harvard, Vancouver, ISO, and other styles

21

Morita, Kiyomi, Guillermo Montalban Bravo, Koji Sasaki, et al. "Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)." Blood 136, Supplement 1 (2020): 21–22. http://dx.doi.org/10.1182/blood-2020-140614.

Full text

Abstract:

Introduction: Guadecitabine (SGI-110) is a next-generation hypomethylating agent (HMA) not metabolized by cytidine deaminase, a common pathway of decitabine deactivation. A multicenter phase II study has shown the clinical activity of guadecitabine in patients (pts) with intermediate and high-risk MDS (Lancet Heme 2019). Here we present an update of a single center phase II study of guadecitabine for pts with previously untreated higher risk MDS. Methods: 100 pts with higher risk MDS or chronic myelomonocytic leukemia (CMML, IPSS INT-2 or high, or bone marrow [BM] blast ≥10%) were treated unde

APA, Harvard, Vancouver, ISO, and other styles

22

Hofste op Bruinink, Davine, Mark van Duin, Meral Beksac, et al. "Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial." Blood 132, Supplement 1 (2018): 3186. http://dx.doi.org/10.1182/blood-2018-99-119873.

Full text

Abstract:

Abstract Background The introduction of proteasome inhibitors (PIs) and immune modulatory drugs (IMiDs) to multiple myeloma (MM) treatment protocols has drastically improved the overall quality and duration of response. This rationalized challenging the role of upfront high dose melphalan (HDM) followed by autologous stem cell transplantation (ASCT) versus chemotherapy alone as intensification treatment in four recent phase III trials. Yet, these showed uniformly that upfront HDM is still superior to non-transplant intensification alternatives including PIs and/or IMiDs. However, HDM's mechani

APA, Harvard, Vancouver, ISO, and other styles

23

Terragna, Carolina, Andrea Poletti, Vincenza Solli, et al. "Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma." Blood 134, Supplement_1 (2019): 1778. http://dx.doi.org/10.1182/blood-2019-127799.

Full text

Abstract:

Multiple Myeloma (MM) maintenance therapy is a low intensive, prolonged treatment, commonly administered to newly diagnosed patients (pts) at the end of fixed-time, front-line regimens. Lenalidomide (LEN) is considered the best available maintenance option for MM able to prolong pts survival. However, the actual benefits or disadvantages of a LEN-based continuous maintenance and its potential role as selective pressure able to induce genomic changes are still unclear. The identification of specific therapy-driven modifications has been so far prevented by the scarce number of homogeneously-tre

APA, Harvard, Vancouver, ISO, and other styles

24

Duchmann, Matthieu, Jean-Baptiste Micol, Nicolas Duployez, et al. "Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML." Blood 134, Supplement_1 (2019): 1416. http://dx.doi.org/10.1182/blood-2019-127082.

Full text

Abstract:

Background : Point mutations in isocitrate dehydrogenase (IDH) genes are seen in 20% of adult patients (pts) with acute myeloid leukemia (AML). Prognostic significance of each IDH1/2 mutation (mut) analyzed with co-occurring mutations treated with intensive chemotherapy (IC) remains inconsistent, particularly with the advent of IDH inhibitors. Furthermore, the role of allogeneic stem cell transplantation (SCT) in IDH-mutated without favorable-risk features is not known. Patients & Methods: Between 2009 and 2016, 262 pts with IDH1/2 mutated AML (101 IDH1mut, 115 IDH2R140Qmutand 46 IDH2R172m

APA, Harvard, Vancouver, ISO, and other styles

25

Montalban Bravo, Guillermo, Rashmi Kanagal-Shamanna, Veronia Guerra, et al. "Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia." Blood 136, Supplement 1 (2020): 26–29. http://dx.doi.org/10.1182/blood-2020-137212.

Full text

Abstract:

INTRODUCTION: The current WHO definition requires presence of persistent absolute monocytosis for the diagnosis of chronic myelomonocytic leukemia (CMML). Oligomonocytic CMML (O-CMML), defined by presence of clinical and pathological features of CMML in the presence of an absolute monocyte count (AMC) of 0.5-0.9x109/L and ³10% monocytes, has been proposed as a unique entity. To date, there is scarce data on the clonal architecture, optimal therapeutic management and survival outcomes of these patients (pts) compared to those with classical CMML. METHODS: We evaluated all untreated pts who met

APA, Harvard, Vancouver, ISO, and other styles

26

Montoro, Maria Julia, Margarita Ortega, Guillermo Villacampa, et al. "A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories." Blood 136, Supplement 1 (2020): 9–10. http://dx.doi.org/10.1182/blood-2020-136197.

Full text

Abstract:

Introduction: Although the IPSS-R stratifies patients with MDS in five risk groups and includes an intermediate-risk group, treatment options are commonly based on the division of the patients into low-risk MDS (LR-MDS) and high-risk MDS (HR-MDS). However, it is not well-defined which cut-off better classifies patients in LR-MDS vs. HR-MDS and, specifically, to which category belongs the intermediate IPSS-R group. A prior study from the International Working Group for the Prognosis of MDS suggested that a cut-off of ≤3.5 points was adequate to identify LR-MDS patients. The aim of the study was

APA, Harvard, Vancouver, ISO, and other styles

27

Benajiba, Lina, Nina Fenouille, Edyta Malolepsza, et al. "Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia." Blood 130, Suppl_1 (2017): 880. http://dx.doi.org/10.1182/blood.v130.suppl_1.880.880.

Full text

Abstract:

Abstract Mammalian cells have developed sophisticated defense mechanisms to counteract a wide variety of stresses to which they are continuously exposed. These adaptive mechanisms are rewired in cancers, such as acute myeloid leukemia (AML), to permit oncogenic transformation (Luo J et al, Cell, 2009). Using an MLL-AF9 syngeneic mouse model, we performed a pooled in vivo shRNA screen intended to identify novel stress response vulnerabilities in AML. p97 / VCP, an AAA-ATPase protein chaperone known to be involved in protein homeostasis and ER stress, was identified as a top candidate. We first

APA, Harvard, Vancouver, ISO, and other styles

28

Diamantopoulos, Panagiotis T., Vassiliki Pappa, Nora-Athina Viniou, et al. "The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome." Blood 134, Supplement_1 (2019): 5427. http://dx.doi.org/10.1182/blood-2019-127417.

Full text

Abstract:

Background: The currently used prognostic systems for myelodysplastic syndromes (MDS) do not consider the prognostic role of monocytopenia, although monocytes may participate in the prognosis of the disease as part of the host immunity. Aim: We studied the prognostic significance of monocytopenia in patients with MDS registered in the Hellenic National MDS registry. Methods: We analyzed clinicopathological data from patients with MDS recorded in a large retrospective national registry. Patients with MDS/MPN were excluded, while patients treated with allogeneic hematopoietic cell transplantatio

APA, Harvard, Vancouver, ISO, and other styles

29

Bohers, Elodie, Pierre-Julien Viailly, Philippe Ruminy, et al. "Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study)." Blood 134, Supplement_1 (2019): 2765. http://dx.doi.org/10.1182/blood-2019-124444.

Full text

Abstract:

Introduction The outcome of very elderly patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) remains poorer than that of younger patients, often because of co-morbidities and physiological organ function impairment. However, the biological specificities of DLBCL in very elderly patients are unknown. The LYSA conducted a multicentric, phase III, open-label, randomized trial in newly diagnosed DLBCL > 80y evaluating the efficacy of the combination of lenalidomide with R-miniCHOP (R2-miniCHOP) in comparison to the standard R-miniCHOP (SENIOR trial, NCT02128061). Based on target

APA, Harvard, Vancouver, ISO, and other styles

30

Cerrano, Marco, Marie Passet, Loic Vasseur, et al. "Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC)." Blood 134, Supplement_1 (2019): 2700. http://dx.doi.org/10.1182/blood-2019-127475.

Full text

Abstract:

Context . AML patients (pts) with a high number of drivers have a poor prognosis (Papaemmanuil, NEJM 2016). Whether this unfavorable outcome is caused by clonal heterogeneity or by a high mutational load in the dominant clone remains undetermined. So far, the prognostic impact of clonal heterogeneity in AML has only been studied in pts with complex karyotypes, where it worsens prognosis (Bochtler, JCO 2013). We addressed this question in a two-center cohort of AML pts treated with IC. Methods . We retrospectively evaluated AML pts treated with IC from 2 centers with targeted sequencing of a 43

APA, Harvard, Vancouver, ISO, and other styles

31

Darwish, Tamer K., Abdul Fattaah Mohamed, Geoffrey Wood, Satwinder Singh, and Jocelyne Fleming. "Can HRM alleviate the negative effects of the resource curse on firms? Evidence from Brunei." Personnel Review 46, no. 8 (2017): 1931–47. http://dx.doi.org/10.1108/pr-04-2016-0081.

Full text

Abstract:

Purpose The resource curse literature suggests that firms operating in non-oil and non-gas industries in petrostates face considerable challenges in securing competitiveness and sustaining themselves. Based on a firm-level survey within a micro-petrostate, Brunei, the purpose of this paper is to explore the relationship between specific HR policies and practices and organisational performance; analyse, compare, and contrast oil and gas with non-oil and non-gas sectors; and draw out the comparative lessons for understanding the potential and performance consequences of HR interventions in resou

APA, Harvard, Vancouver, ISO, and other styles

32

D'Agostino, Mattia, Marina Ruggeri, Sara Aquino, et al. "Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial." Blood 136, Supplement 1 (2020): 38–40. http://dx.doi.org/10.1182/blood-2020-137060.

Full text

Abstract:

Background Copy-number alterations of chromosome 1q are frequently found in multiple myeloma (MM) and are associated with poor prognosis. Recently, it has been demonstrated that the number of 1q copies correlates with a high-risk behavior (BA Walker et al, Leukemia 2019, TM Schmidt et al, Blood Cancer J 2019), but no data are available in carfilzomib-treated patients (pts). Here we aim at dissecting the role of Gain1q (3 copies of 1q) vs amplification 1q (Amp1q, ≥4 copies of 1q) in carfilzomib-treated NDMM pts enrolled in the randomized FORTE trial (NCT02203643). Methods Fluorescence in situ h

APA, Harvard, Vancouver, ISO, and other styles

33

Morita, Kiyomi, Hagop M. Kantarjian, Hong Fang, et al. "Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression." Blood 136, Supplement 1 (2020): 38–40. http://dx.doi.org/10.1182/blood-2020-140590.

Full text

Abstract:

Introduction: T-cell acute lymphoblastic leukemia (T-ALL) originating from early T-cell precursors (ETP-ALL) has distinct immunophenotype (CD1a-CD8-CD5-/weak and positive for myeloid or stem-cell markers [My-HSC+]) and is associated with poor outcome with 5-year (yr) survival &lt;25%. Some T-ALL cases are transcriptionally similar to ETP-ALL but the level of CD5 expression is not low enough to meet the immunophenotypic criteria of ETP-ALL (near-ETP ALL), and their outcome remains unknown (Coustan-Smith et al. Lancet Oncol 2009). The aim of this study is to characterize the patients (pts) w

APA, Harvard, Vancouver, ISO, and other styles

34

Maifrede, Silvia, Bac Viet Le, Margaret Nieborowska-Skorska, et al. "TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors." Blood 136, Supplement 1 (2020): 4. http://dx.doi.org/10.1182/blood-2020-137658.

Full text

Abstract:

Somatic variants in TET2 and DNMT3A are founding mutations in hematological malignancies that both affect the epigenetic regulation of DNA methylation. Although the proteins antagonistically regulate the epigenetic mark of 5-methylcytosine (5-mC), where DNMT3A catalyzes addition of 5-mC while TET2 oxidizes 5-mC as a first step in DNA demethylation, mutations in both genes appear in a similar spectrum of human hematopoietic malignancies. Mutations in both genes often co-occur with activating mutations in oncogenic tyrosine kinases (OTKs) such as FLT3ITD, BCR-ABL1, JAK2V617F, MPLW515L or mutatio

APA, Harvard, Vancouver, ISO, and other styles

35

Giebel, Sebastian, Myriam Labopin, Wlodzimierz Mendrek, et al. "The Use of Anti-Thymocyte Globulin Is Associated with Increased Chance of Survival Free from Relapse and Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation for Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT." Blood 128, no. 22 (2016): 666. http://dx.doi.org/10.1182/blood.v128.22.666.666.

Full text

Abstract:

Abstract BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered a standard of care for adults with high risk Philadelphia-negative acute lymphoblastic leukemia (Ph-neg ALL). During the last decade mobilized peripheral blood stem cells (PBSCT) has become predominant source of graft for allo-SCT. However, as compared to bone marrow, PBSCT is associated with increased risk of chronic graft-versus-host disease (cGVHD). Attempts to reduce the cGVHD rate include the addition of anti-thymocyte globulin (ATG) to the conditioning regimen. The goal of this registry-based

APA, Harvard, Vancouver, ISO, and other styles

36

Romano, Alessandra, Francesca Palandri, Lucia Masarova, et al. "Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience." Blood 132, Supplement 1 (2018): 4303. http://dx.doi.org/10.1182/blood-2018-99-116418.

Full text

Abstract:

Abstract Background Myelofibrosis (MF) is featured by an inflammatory condition that can also drive the progression of disease. Ruxolitinib (RUX) is the-first-in-class Jak1/2 inhibitor approved for treatment for MF. Clinical benefits of RUX are presumably derived from reduction of inflammatory cytokines even if the exact mechanism remains unclear. Recent reports have identified the ratio between absolute neutrophils count (ANC) and absolute lymphocyte count (ALC), called NLR, as a simple parameter that mirrors the inflammatory status and the myeloid associated immune suppression. In various ma

APA, Harvard, Vancouver, ISO, and other styles

37

Симонова and Marina Simonova. "Trends in development of competencies of HR managers." Administration 1, no. 2 (2013): 100–103. http://dx.doi.org/10.12737/1983.

Full text

Abstract:

In today´s economy more and more importance is the development of competencies and qualifications that affect not only the competitiveness of the labor force in the labor market, but also the competitiveness of the organization, which attracts a certain quality staff for the purposes of production. A key role in achieving the goals of the staff through the use of advanced technology should play HR managers, their competence and skills depends on their status in the organization and implementation of the employment potential of the organization. Increasingly, the most qualified personnel manage

APA, Harvard, Vancouver, ISO, and other styles

38

Abraham, Ivy, Garth Rauscher, Anand Ashwin Patel, et al. "The Role of Structural Violence in Acute Myeloid Leukemia Outcomes." Blood 136, Supplement 1 (2020): 10. http://dx.doi.org/10.1182/blood-2020-136379.

Full text

Abstract:

Background: Non-Hispanic Black (NHB) and Hispanic patients with Acute Myeloid Leukemia (AML) have higher mortality rates than non-Hispanic white (NHW) patients despite lower incidence, more favorable genetics, and a younger age at presentation (Darbinyan, Blood Adv. 2017). We performed a multilevel analysis of disparities in AML patients to investigate the contribution of structural violence, specifically neighborhood SES, on racial/ethnic differences in leukemia-specific survival. Methods: Adult AML (non-APL) patients diagnosed between 2012 and 2018 at six academic cancer centers in the Chica

APA, Harvard, Vancouver, ISO, and other styles

39

Hill, Elizabeth, Neha Korde, Sham Mailankody, et al. "Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree." Blood 134, Supplement_1 (2019): 1794. http://dx.doi.org/10.1182/blood-2019-126952.

Full text

Abstract:

Introduction Defining high risk (HR) smoldering multiple myeloma (SMM) is becoming increasingly important as multiple clinical trials are actively investigating the role of early treatment. On average, patients with SMM progress to multiple myeloma (MM) at a rate of 10% per year for the first 5 years (Kyle 2007). Several classification systems have been developed to identify patients with a higher rate of progression, including two commonly used models: the 2008 Mayo Clinic model and the PETHEMA (Programa de Estudio y Tratamiento de las Hemopatias Malignas) model. The 2008 Mayo Clinic model in

APA, Harvard, Vancouver, ISO, and other styles

40

Saini, Neeraj, Junsheng Ma, Melissa Timmons, et al. "High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC)." Blood 136, Supplement 1 (2020): 32–33. http://dx.doi.org/10.1182/blood-2020-134471.

Full text

Abstract:

Background Most PMBCL pts are cured with frontline chemoimmunotherapy ± RT. Data are scant regarding the role of HDC/ASCT for R/R PMBCL, and the benefit of RT administered peri-HDC/ASCT. Our institutional approach has focused on developing potentially more active HDC regimens, and on consideration of post-ASCT consolidation RT, especially for pts who had not achieved a CR at the time of HDC. Methods We retrospectively analyzed all patients (pts) with R/R PMBCL treated with HDC/ASCT at MDACC between 01/01/2000-12/31/2019. All pts underwent similar standard pre-SCT evaluation and met eligibility

APA, Harvard, Vancouver, ISO, and other styles

41

Bushueva, I., E. Andreeva, and A. Kryukova. "Development of a Map of HR Trends and Technologies." Management of the Personnel and Intellectual Resources in Russia 10, no. 2 (2021): 46–50. http://dx.doi.org/10.12737/2305-7807-2021-10-2-46-50.

Full text

Abstract:

Currently, the emergence and development of technologies, including in personnel management, is happening at an exponential speed. The use of modern HR trends and technologies allows organizations to meet the requirements of the time. Despite a significant number of studies of trends in HR and related forecasts, this information requires generalization, structuring and visual presentation. Presented in the article «Map of HR trends and technologies» gives an idea of the development directions of existing and future HR trends and technologies for the period 2020-2040. The developed map pr

APA, Harvard, Vancouver, ISO, and other styles

42

Kothari, Shalin K., Shaoying Li, L. Jeffrey Medeiros, et al. "Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers." Blood 132, Supplement 1 (2018): 451. http://dx.doi.org/10.1182/blood-2018-99-111530.

Full text

Abstract:

Abstract Introduction: Patients (pts) with limited stage (LS) aggressive large B-cell lymphoma (ALBCL) comprise 30-40% of ALBCLs and are usually treated with R-CHOP with or without consolidative involved field radiation therapy (IFRT). In pts with ALBCL, cytogenetic studies have identified a subset with high-risk disease who harbor MYC rearrangement (MYC-R) with or without BCL2 (BCL2-R) and/or BCL6 (BCL6-R) rearrangements. This has led to the adoption of intensive induction strategies in this population; however, it is unclear if such an approach is necessary in limited stage disease. Methods:

APA, Harvard, Vancouver, ISO, and other styles

43

Daher-Reyes, Georgina S., TaeHyung Kim, Kyoung Ha Kim, et al. "Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia." Blood 134, Supplement_1 (2019): 3317. http://dx.doi.org/10.1182/blood-2019-125780.

Full text

Abstract:

Introduction: The introduction of next-generation sequencing (NGS) has expedited the discovery of novel genetic lesions in acute myeloid leukemia (AML), thereby allowing better risk stratification with respect to overall survival (OS). We have previously reported that AML patients with PTPN11 and NPM1 mutations had longer OS following chemotherapy, while those carrying mutations in ASXL1, JAK2, RUNX1, TP53 and SRSF2 had a shorter OS (Daher-Reyes,ASH 2018). Little is known, however, regarding the impact of genetic profiles (somatic mutations and cytogenetic abnormalities) at initial AML diagnos

APA, Harvard, Vancouver, ISO, and other styles

44

Ramos Perez, Jorge M., Tapan M. Kadia, Guillermo Montalban-Bravo, et al. "Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)." Blood 136, Supplement 1 (2020): 32–34. http://dx.doi.org/10.1182/blood-2020-142570.

Full text

Abstract:

INTRODUCTION: The outcome of patients (pts) with relapsed or refractory AML (R/R AML) or MDS after failing hypomethylating agents (HMA) and/or BCL-2 inhibitor combinations is poor. CPX-351 is a liposomal formulation of cytarabine and daunorubicin, approved by the US Food and Drug Administration (FDA) for newly diagnosed therapy related AML or AML with myelodysplastic related changes. GO is a humanized immunoglobulin G4 antibody directed against CD33 and conjugated to the DNA toxin calicheamicin, also approved by the FDA for the treatment of newly diagnosed or R/R CD33-positive AML. We have hyp

APA, Harvard, Vancouver, ISO, and other styles

45

Cerrato, Chiara, Francesca Gay, Maria Teresa Petrucci, et al. "Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients." Blood 126, no. 23 (2015): 1974. http://dx.doi.org/10.1182/blood.v126.23.1974.1974.

Full text

Abstract:

Abstract Introduction Several trials have shown that maintenance therapy prolongs progression-free survival (PFS) in multiple myeloma (MM) patients, eligible and ineligible for autologous stem cell transplantation (ASCT); conflicting data exist about its impact on overall survival (OS). The role of maintenance in patients with a sensitive disease is still unclear. We conducted a retrospective pooled analysis to clarify the impact of continuous treatment in patients achieving a complete response (CR). Methods Data from newly diagnosed MM patientsenrolled in 4 phase III trials were analysed. Two

APA, Harvard, Vancouver, ISO, and other styles

46

Steensma, David P., Martin Wermke, Virginia M. Klimek, et al. "Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)." Blood 134, Supplement_1 (2019): 673. http://dx.doi.org/10.1182/blood-2019-123854.

Full text

Abstract:

Background: Heterozygous somatic mutations in the genes encoding RNA splicing factors SF3B1, U2AF1, SRSF2 or ZRSR2 induce aberrant splicing in cancer cells and are among the most common mutations in patients with MDS, AML or CMML. H3B-8800 is an orally available small molecule that binds to the SF3b complex and induces alternative splicing changes in cells. Because splicing factor mutant cells depend on residual wild-type function of splicing factors for survival, we hypothesized that H3B-8800 would induce preferential cell killing of mutant cells by further perturbing splicing to synthetic le

APA, Harvard, Vancouver, ISO, and other styles

47

Cavo, Michele, Meral Beksac, Meletios A. Dimopoulos, et al. "Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)." Blood 128, no. 22 (2016): 673. http://dx.doi.org/10.1182/blood.v128.22.673.673.

Full text

Abstract:

Abstract Background The role of upfront autologous stem cell transplantation (ASCT) for younger patients with newly diagnosed (ND) multiple myeloma (MM) has been questioned in the novel agent era. Methods A prospective, multicenter, phase III study was designed to compare (first randomization, R1) (1:1 ratio; stratification according to ISS stage) four 42-day cycles of bortezomib-melphalan-prednisone (VMP) given at the same dosing schedule reported in the VISTA study (NEJM 2008; 359:906-17) vs either a single course or two sequential courses of melphalan at 200 mg/m2 (HDM) followed by single o

APA, Harvard, Vancouver, ISO, and other styles

48

Srour, Samer A., Yago Nieto, Swaminathan P. Iyer, et al. "Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma." Blood 136, Supplement 1 (2020): 40–41. http://dx.doi.org/10.1182/blood-2020-142889.

Full text

Abstract:

Introduction: Peripheral T-cell lymphoma (PTCL) comprises a heterogeneous group of rare neoplasms, the majority characterized by an aggressive course and short survival. Angioimmunoblastic T-cell lymphoma (AITL) is the second most common subtype (19%) of PTCLs, with generally poor long-term prognosis. The outcomes for most reported cases of AITL are derived from cohorts which include other PTCL subtypes. There is limited data for the role of autologous stem cell transplantation (ASCT) in AITL, and the associated predictive factors for prognosis. We present the largest single center cohort of A

APA, Harvard, Vancouver, ISO, and other styles

49

Sonneveld, Pieter, Meral Beksac, Bronno van der Holt, et al. "Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)." Blood 128, no. 22 (2016): 242. http://dx.doi.org/10.1182/blood.v128.22.242.242.

Full text

Abstract:

Abstract Background The role of up-front consolidation for newly diagnosed, transplant eligible MM (NDMM) patients (pts) has not yet been prospectively addressed in the novel agents era. Methods The EMN02/HO95 trial was designed to randomly (R) compare (R1) 4 cycles of bortezomib-melphalan-prednisone (VMP) vs high-dose melphalan (HDM) and autologous stem cell transplantation (ASCT), either single or double, as intensification therapy after induction with bortezomib-cyclophosphamide-dexamethasone (VCD) (M Cavo et al, ASCO 2016, abstract #8000). A second randomization to consolidation therapy wi

APA, Harvard, Vancouver, ISO, and other styles

50

Solimando, Antonio Giovanni, Matteo Claudio Da Via', Patrizia Leone, et al. "Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival." Blood 134, Supplement_1 (2019): 855. http://dx.doi.org/10.1182/blood-2019-126674.

Full text

Abstract:

Multiple myeloma (MM) plasma cell (MMPC) interactions with the microenvironment control MMPC growth, survival, drug-resistance and intra- and extramedullary dissemination. Dissemination of MMPCs through bone marrow niches and in extra-medullary sites is an active process of invasion involving bone marrow endothelial cells, multiple adhesion molecules and chemokine receptors. Since enhanced angiogenesis characterizes MM, we investigated whether junctional adhesion molecule-A (JAM-A) mediated interactions between MM bone marrow endothelial cells (MMECs) and MMPCs impact disease progression. To t

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!